menu search

ANGO / AngioDynamics, Inc.'s (ANGO) CEO Jim Clemmer on Q4 2022 Results - Earnings Call Transcript

AngioDynamics, Inc.'s (ANGO) CEO Jim Clemmer on Q4 2022 Results - Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO ) Q4 2022 Earnings Conference Call July 12, 2022 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James William Plovanic - Canaccord Matthew Mishan - KeyBanc Capital Markets Operator Good morning, and welcome to AngioDynamics' Fourth Quarter and Fiscal Year 2022 Earnings Call. At this time, all participants are in a listen-only mode. Read More
Posted: Jul 12 2022, 12:52
Author Name: Seeking Alpha
Views: 111729

ANGO News  

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

By Zacks Investment Research
October 6, 2023

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP. more_horizontal

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

By Zacks Investment Research
October 5, 2023

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024. more_horizontal

Why Angiodynamics Stock Sank Today

By The Motley Fool
October 4, 2023

Why Angiodynamics Stock Sank Today

The medical device and technology specialist unveiled its latest set of quarterly results. Its bottom line was in the red and only marginally beat est more_horizontal

AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
October 4, 2023

AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates

AngioDynamics (ANGO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss o more_horizontal

AngioDynamics: Enormous Effort Required In Fiscal '24 To Reverse The Equity Picture

By Seeking Alpha
September 17, 2023

AngioDynamics: Enormous Effort Required In Fiscal '24 To Reverse The Equity Picture

AngioDynamics, Inc. posted mixed results in its FY'23 reports, with strong growth in its Med Tech division. The company's focus going forward will be more_horizontal

AngioDynamics (ANGO) Flat As Market Sinks: What You Should Know

By Zacks Investment Research
August 17, 2023

AngioDynamics (ANGO) Flat As Market Sinks: What You Should Know

AngioDynamics (ANGO) closed at $8.58 in the latest trading session, marking no change from the prior day. more_horizontal

AngioDynamics' (ANGO) New FDA Recognition to Boost Treatment

By Zacks Investment Research
August 16, 2023

AngioDynamics' (ANGO) New FDA Recognition to Boost Treatment

The FDA's grant of the Breakthrough Device designation for AngioDynamics' (ANGO) AngioVac is likely to remove thrombus and embolic material and minimi more_horizontal

AngioDynamics (ANGO) Lags Q4 Earnings Estimates

By Zacks Investment Research
July 12, 2023

AngioDynamics (ANGO) Lags Q4 Earnings Estimates

AngioDynamics (ANGO) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.03 per share. This compares to ea more_horizontal


Search within

Pages Search Results: